arrow
B

Benedikt Simbrunner

Medical University of Vienna
H指数:32
被引数:3,348

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Blood- and Liver Stiffness-Based Non-Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC

基于血液和肝脏硬度检测的无创性检查在慢性肝纤维化相关肝硬化及肝癌患者中临床显著门静脉高压的诊断应用

2026-10-280
OAAI
Intestinal barrier dysfunction assessed by confocal laser endomicroscopy correlates with cirrhosis severity and clinical outcome☆

通过共聚焦激光内镜评估的肠道屏障功能障碍与肝硬化严重程度和临床结局相关<sup>☆</sup>

2026-09-180
OA
Stage-specific drivers of clinical progression in advanced chronic liver disease

晚期慢性肝病临床进展的分期特异性驱动因素

2026-06-170
PRE
Characterization of liver disease regression in murine models of liver fibrosis and portal hypertension

肝纤维化和门静脉高压小鼠模型中肝脏疾病回退的表征

2026-06-140
OAAI
The Link of Portal-Hypertensive Gastropathy to Anaemia, Systemic Inflammation and Disease Progression in Cirrhosis

门静脉高压性胃病与肝硬化贫血、全身炎症及疾病进展的关联

2026-05-220
OAAI
Prognostication of Liver Disease Patients via the WFUMB ‘Rule-of-4’ Algorithm Using SSI-2D-SWE-Based Liver Stiffness Measurement

基于SSI-2D-SWE肝脏硬度测量的WFUMB‘4规则’算法对肝病患者的预后预测

2026-04-090
OAAI
The Alpha-1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD
2026-01-230
OAAI
GDF-15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical Outcomes
2026-01-190
OAAI
Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease-Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute-on-Chronic Liver Failure and Death

靛青绿清除率与反映晚期慢性肝病关键疾病驱动机制的生物标志物相关,并可预测急性-慢性肝功能衰竭及死亡。

2025-11-050
OAAI
Alcohol Use After TIPS Implantation Significantly Increases the Risk of ACLF and Liver-Related Death

TIPS植入术后饮酒显著增加ACLF和肝脏相关死亡的风险

2025-11-011
PRE
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver disease

基于血液的维也纳3P/5P风险模型可准确预测代偿期晚期慢性肝病患者的首次肝功能失代偿。

2025-10-170
OAAI
Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease

细胞外基质重塑的生物标志物与晚期慢性肝病的严重程度和预后相关

2025-10-120
OAAI
Stage-dependent Effects of Systemic ASBT Inhibition in a Cholestasis-induced Cholemic Nephropathy Mouse Model

系统ASBT抑制在胆汁淤积诱导的胆汁性肾病小鼠模型中的阶段依赖性效应

2025-09-230
OAAI
Neutrophil Extracellular Traps Are Not Linked to Decompensation, ACLF, or Death in Clinically Stable Patients With ACLD

中性粒细胞胞外陷阱与临床稳定的ACLD患者的失代偿、ACLF或死亡无关

2025-09-180
OAAI
IgM Antibodies Targeting Malondialdehyde Promote Complement-Mediated Liver Injury in Alcohol-Related Liver Disease

靶向丙二醛的IgM抗体促进酒精性肝病中补体介导的肝损伤

2025-09-170
OAAI
Erratum to ‘Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis’ [J Hepatol 83 (2025) 70–80]

勘误:‘Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis’ [J Hepatol 83 (2025) 70–80]

2025-09-050
PRE